Randomized trial · people
Larazotide: no gut permeability rise after gluten in celiac patients
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This early trial found single doses of larazotide were well tolerated in celiac patients, with no rise in gut leakiness after gluten in the larazotide group.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2007
- Journal
- Aliment Pharmacol Ther
What they tested
The team tested whether 12 mg doses of larazotide (AT-1001) were safe and well tolerated in people with celiac disease who were given gluten.
How the study was done
A double-blind, randomized, placebo-controlled safety trial in hospital in-patients with celiac disease, comparing single doses of larazotide with placebo (a dummy treatment) during a gluten challenge. Gut permeability, meaning how leaky the intestinal lining is, was measured with lactulose and mannitol urine tests as an exploratory check of whether the drug worked.

What they found
Side effects were no more common with larazotide than with placebo. After the gluten exposure, gut permeability rose 70% in the placebo group, while no rise was seen in the larazotide group. Interferon-gamma, a marker of inflammation, went up in 57% of placebo patients compared with 29% of larazotide patients. Gut symptoms showed up more often in the placebo group (P = 0.018).
What it doesn’t show
This was a small safety study using single doses during a short gluten challenge, so it does not show what happens with longer use. The permeability results were an exploratory measure, not the main goal of the trial.
The paper
Paterson et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007.
The compound
More studies on Larazotide
- Larazotide: eased GI symptoms in celiac patients on gluten challengeMeta-analysis · people · 2022
- Every study on Larazotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.